

### HIV/AIDS AGENTS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **HIV/AIDS Agents** and **Quantity Limits/Daily Dose Limits** are available at  
<http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	
Name of office contact:		Prescriber name:	
Contact's phone number:		Specialty:	
LTC facility contact/phone:		State license #:	MA Provider ID#:
<b>BENEFICIARY INFORMATION</b>		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

Non-preferred medication requested			
<input type="checkbox"/> abacavir/lamivudine tablet	<input type="checkbox"/> Intelence tablet	<input type="checkbox"/> Prezobix tablet	<input type="checkbox"/> Videx EC capsule
<input type="checkbox"/> abacavir/lamivudine/zidovudine tab	<input type="checkbox"/> Invirase capsule/tablet	<input type="checkbox"/> Rescriptor tablet	<input type="checkbox"/> Viracept tablet
<input type="checkbox"/> Aptivus capsule/solution	<input type="checkbox"/> Isentress powder	<input type="checkbox"/> Retrovir capsule/injection/syrup	<input type="checkbox"/> Viramune suspens
<input type="checkbox"/> atazanavir capsule	<input type="checkbox"/> Isentress HD tablet	<input type="checkbox"/> ritonavir tablet	<input type="checkbox"/> Viramune XR table
<input type="checkbox"/> Combivir tablet	<input type="checkbox"/> Juluca tablet	<input type="checkbox"/> Selzentry solution/tablet	<input type="checkbox"/> Zerit capsule/soluti
<input type="checkbox"/> Crixivan capsule	<input type="checkbox"/> lamivudine solution	<input type="checkbox"/> tenofovir DF tablet	<input type="checkbox"/> Ziagen tablet
<input type="checkbox"/> efavirenz capsule/tablet	<input type="checkbox"/> Lexiva suspension/tablet	<input type="checkbox"/> Trimeq tablet	<input type="checkbox"/>
<input type="checkbox"/> EpiVir tablet	<input type="checkbox"/> lopinavir/ritonavir solution	<input type="checkbox"/> Trizivir tablet	
<input type="checkbox"/> fosamprenavir tablet	<input type="checkbox"/> nevirapine ER tablet	<input type="checkbox"/> Tybost tablet	
<input type="checkbox"/> <b>Fuzeon vial* (specialty drug)</b>			

Strength: _____	Dosage form: <input type="checkbox"/> capsule <input type="checkbox"/> tablet <input type="checkbox"/> suspension/solution <input type="checkbox"/> injection <input type="checkbox"/> powder <input type="checkbox"/> other: _____
-----------------	---

Directions:	Quantity:
-------------	-----------

Diagnosis:	Dx code (required):
------------	---------------------

*Fuzeon injection is part of the Specialty Pharmacy Drug Program. Which specialty pharmacy will be used?	<input type="checkbox"/> Diplomat Specialty Pharmacy <input type="checkbox"/> Walgreen's Specialty Pharmacy
--	--

1. Has the Beneficiary been taking the requested non-preferred HIV/AIDS Agent within the past 90 days?	<input type="checkbox"/> Yes – <i>Submit all supporting documentation of drug regimen and treatment outcome.</i> <input type="checkbox"/> No
--	---

2. Check all preferred agents in the lists below that the Beneficiary tried and failed, or has a contraindication, intolerance, or resistance to, <u>and submit all supporting documentation.</u>			
<input type="checkbox"/> abacavir solution/tablet <input type="checkbox"/> Cimduo tablet <input type="checkbox"/> Descovy tablet <input type="checkbox"/> didanosine DR capsule <input type="checkbox"/> Emtriva capsule/solution <input type="checkbox"/> EpiVir solution	<b>NRTIs</b> <input type="checkbox"/> lamivudine/zidovudine tab <input type="checkbox"/> stavudine capsule <input type="checkbox"/> Truvada tablet <input type="checkbox"/> Videx solution <input type="checkbox"/> Viread tablet/powder <input type="checkbox"/> Ziagen solution	<b>NNRTIs</b> <input type="checkbox"/> Edurant tablet <input type="checkbox"/> nevirapine tablet <input type="checkbox"/> Sustiva capsule/tablet  <b>Protease Inhibitors</b> <input type="checkbox"/> Evoxaz tablet	<b>Complete Regimen Product</b> <input type="checkbox"/> Atripla tablet <input type="checkbox"/> Biktarvy tablet <input type="checkbox"/> Complera tablet <input type="checkbox"/> Genvoya tablet <input type="checkbox"/> Odefsey tablet <input type="checkbox"/> Stribild tablet

R e f i l i s :

<input type="checkbox"/> Epzicom tablet	<input type="checkbox"/> zidovudine cap/tab/syrup	<input type="checkbox"/> Kaletra solution/tablet	<input type="checkbox"/> Symfi tablet
<input type="checkbox"/> lamivudine tablet		<input type="checkbox"/> Norvir solution/tablet	<input type="checkbox"/> Symfi Lo tablet
		<input type="checkbox"/> Prezista suspension/tablet	
		<input type="checkbox"/> Reyataz capsule/powder	
			<b><u>Integrase Inhibitors</u></b>
			<input type="checkbox"/> Isentress chewable/tablet
			<input type="checkbox"/> Tivicay tablet

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended beneficiary, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.